Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149459 | 0.93 | L3MBTL1 (0.49) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3149140 | 0.92 | L3MBTL1 (0.50) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3153219 | 0.92 | KMT2A (0.51) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3143520 | 0.90 | KMT2A (0.49) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3153442 | 0.88 | L3MBTL1 (0.45) | ALDH1A1GAAKMT2AL3MBTL1CCR2 | |
| SCHEMBL3154567 | 0.87 | CCR2 (0.48) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3157725 | 0.87 | CCR2 (0.55) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3153568 | 0.86 | CCR2 (0.57) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3156345 | 0.84 | CCR2 (0.54) | ALDH1A1GAASMN1; SMN2PKMMAPK1 | |
| SCHEMBL3148226 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAASMN1; SMN2PKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | ALDH1A1 3552/4885GAA 4410/4885SMN1; SMN2 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.